TMS for Adults With Autism and Depression (TAD)

This is an interventional treatment trial for Autism Spectrum Disorder focused on measuring Autism Spectrum Disorder, Autism, Depressive, Depression Read More

Inclusion Criteria:

• Diagnosis of Autism Spectrum Disorder and active depressive symptoms.

Exclusion Criteria:

• List specific contraindicationsUncontrolled and/or untreated seizure disorder as defined by any incidence of seizure within the past 6 months. Patients with diagnosed epilepsy, or prior seizures, will be allowed in the study if they are taking an anticonvulsant medication, or have not had a seizure in the past year off medications.
• Moderate to severe intellectual disability (ID) as defined by IQ < 60, determined by prior IQ testing or Wechsler Abbreviated Scale of Intelligence (WASC-II) if no prior test results available
• Other psychiatric or neurodevelopmental illness that is the primary area of clinical focus (including but not limited to primary psychotic disorder, substance abuse disorder, and ASD or ID which are secondary to genetic syndromes)
• Active suicidal ideation or suicide attempt in the 90 days prior to initial assessment
• Presence of any metal implants or devices in the head or neck (e.g. metal plates or screws)
• No participants who are pregnant or who are planning to become pregnant

• Exclusion criteria for fMRI scanning:

  • have metal pins, plates or clips in the body or have orthodontics
  • have surgical implants such as pacemakers or cochlear implants
  • have permanent makeup or tattoos near the face or head
  • have metal fragments in the body (from welding, shrapnel, BB guns) or suspect that they have fragments
  • are claustrophobic
  • are pregnant
  • have ever suffered a closed head injury or concussion
  • are currently under the influence of alcohol or other recreational drugs
  • are a smoker
  • are currently enrolled in a course in which the PI or co-I's are instructors
  • cannot understand the task instructions
  • cannot lay still in the mock scanner for a period of 6 minutes
• Inability or unwillingness of participant or legal guardian/representative to give informed consent
• There will be no discrimination or exclusions based on race, gender, sexual orientation, or other socioeconomic factors. Of note, while both male and female participants will be actively and equally recruited using the same methods. The natural distribution of autism in the population skews towards significant towards male gender, with male prevalence being 4-5 times that of female prevalence. Our study will therefore likely have more male participants than female due to this trend in prevalence.
• Children (age <18) are being excluded from this study for several reasons. While autism is a pediatric neurodevelopmental disorder with symptom onset as young as one year of age, it is also one that is chronic throughout adulthood. Both children with autism and neurotypical children undergo periods of rapid change in brain size, structure, and organization as they age, and the interaction between a full rTMS series and brains that are still involved in periods of very active development and whom may also be at different points along their own developmental timelines may skew or alter the data that is collected. Additionally, due to both brain growth and increases in skull thickness, children of different ages may have significantly different "scalp to cortex" distances, which can result in very different patterns of cortical stimulation despite uniform coil positioning. This will be an added, unnecessary variable which would compromise the attempt at performing a standardized protocol. Finally, while high frequency rTMS is an FDA approved treatment for depression in adults, it has not yet been FDA approved in children and adolescents.